Drug intelligence / Profile preview

shRNA against Pak1

Development stage
Unknown
Modality
Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Intratumoral, Parenteral, Oral, Intrathecal
01

Overview

shRNA against Pak1 is a short hairpin RNA (shRNA) designed to target and silence the expression of p21-activated kinase 1 (PAK1). PAK1 is a serine/threonine kinase that plays a key role in cell survival, proliferation, and cytoskeletal reorganization, and is frequently overexpressed or hyperactivated in various cancers, including breast cancer and hepatocellular carcinoma. By mediating RNA interference (RNAi), the shRNA leads to the degradation of PAK1 mRNA, resulting in reduced PAK1 protein levels. In research settings, silencing of PAK1 has been shown to inhibit downstream ERK and Akt signaling, restore normal acinar architecture in breast cancer models, and sensitize cancer cells to other therapies [1.1].

Other names
PAK1 shRNAPAK-1 shRNAPAK 1 shRNAshRNA targeting PAK1
02

Targets

PAK1 (p21-activated kinase 1)

Beyond the preview

Go deeper on shRNA against Pak1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on shRNA against Pak1.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call